Albain KS, de la Garza Salazar J, Pienkowski T, Aapro M, Bergh J, Caleffi M, Coleman R, Eiermann W, Icli F, Pegram M, Piccart M, Snyder R, Toi M, Hortobagyi GN: Reducing the global breast cancer burden: the importance of patterns of care research. Clin Breast Cancer 2005, 6(5):412-420. doi:10.3816/CBC.2005.n.045
Article
Google Scholar
Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, Rolski J, Melemed AS, Reyes-Vidal JM, Sekhon JS, Simms L, O’Shaughnessy J: Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008, 26(24):3950-3957. doi:10.1200/jco.2007.11.9362
Article
Google Scholar
Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A: Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 2002, 62(1):2-8.
Article
Google Scholar
Brufsky A, Hoelzer K, Beck T, Whorf R, Keaton M, Nadella P, Krill-Jackson E, Kroener J, Middleman E, Frontiera M, Paul D, Panella T, Bromund J, Zhao L, Orlando M, Tai F, Marciniak MD, Obasaju C, Hainsworth J: A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer. Clin Breast Cancer 2011, 11(4):211-220. doi:10.1016/j.clbc.2011.03.019
Article
Google Scholar
Chan S, Romieu G, Huober J, Delozier T, Tubiana-Hulin M, Schneeweiss A, Lluch A, Llombart A, du Bois A, Kreienberg R, Mayordomo JI, Anton A, Harrison M, Jones A, Carrasco E, Vaury AT, Frimodt-Moller B, Fumoleau P: Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 2009, 27(11):1753-1760. doi:10.1200/jco.2007.15.8485
Article
Google Scholar
Colomer R: Gemcitabine and paclitaxel in metastatic breast cancer: a review. Oncology (Williston Park) 2004, 18(14 Suppl 12):8-12.
Google Scholar
Delfino C, Caccia G, Gonzales LR, Mickiewicz E, Rodger J, Balbiani L, Morales DF, Comba AZ, Brosio C: Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer. Oncology 2004, 66(1):18-23. doi:10.1159/000076330
Article
Google Scholar
Dent S, Messersmith H, Trudeau M: Gemcitabine in the management of metastatic breast cancer: a systematic review. Breast Cancer Res Treat 2008, 108(3):319-331. doi:10.1007/s10549-007-9610-z
Article
Google Scholar
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188.
Article
Google Scholar
Green MR: Gemcitabine safety overview. Semin Oncol 1996, 23(5 Suppl 10):32-35.
Google Scholar
Gudena V, Montero AJ, Gluck S: Gemcitabine and taxanes in metastatic breast cancer: a systematic review. Ther Clin Risk Manag 2008, 4(6):1157-1164.
Google Scholar
Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C: Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008, 8: 82. doi:10.1186/1471-2407-8-82
Article
Google Scholar
Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR: Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002, 20(12):2824-2831.
Article
Google Scholar
Hortobagyi GN, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, Khaled H, Liu MC, Martin M, Namer M, O’Shaughnessy JA, Shen ZZ, Albain KS: The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer 2005, 6(5):391-401.
Article
Google Scholar
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96. doi:10.3322/ca.2007.0010
Article
Google Scholar
Joensuu H, Sailas L, Alanko T, Sunela K, Huuhtanen R, Utriainen M, Kokko R, Bono P, Wigren T, Pyrhonen S, Turpeenniemi-Hujanen T, Asola R, Leinonen M, Hahka-Kemppinen M, Kellokumpu-Lehtinen P: Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial. Ann Oncol 2010, 21(5):968-973. doi:10.1093/annonc/mdp397
Article
Google Scholar
Kakimoto M, Kawashima H, Koshiishi H, Miyamoto H, Okamura T: A case of recurrent breast cancer in which gemcitabine-docetaxel therapy was successful for a long period. Gan To Kagaku Ryoho 2012, 39(12):2086-2087.
Google Scholar
Levy C, Fumoleau P: Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients? Cancer Treat Rev 2005, 31(Suppl 4):S17-S22.
Article
Google Scholar
Li W, Wang H, Li X: Efficacy of gemcitabine-based chemotherapy in metastatic breast cancer: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2013, 29(11):1443-1452. doi:10.1185/03007995.2013.832185
Article
Google Scholar
Markman M, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J: Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol 2003, 90(3):593-596.
Article
Google Scholar
Miles D, von Minckwitz G, Seidman AD: Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist 2002, 7(Suppl 6):13-19.
Google Scholar
Nielsen DL, Bjerre KD, Jakobsen EH, Cold S, Stenbygaard L, Sorensen PG, Kamby C, Moller S, Jorgensen CL, Andersson M: Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group. J Clin Oncol 2011, 29(36):4748-4754. doi:10.1200/jco.2010.33.9507
Article
Google Scholar
Papadimitriou CA, Kalofonos H, Zagouri F, Papakostas P, Bozas G, Makatsoris T, Dimopoulos MA, Fountzilas G: Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group. Oncology 2009, 77(3–4):212-216. doi:10.1159/000236021
Article
Google Scholar
Russo A, Rizzo S, Fulfaro F, Adamo V, Santini D, Vincenzi B, Gebbia N, Carreca I: Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis. Cancer 2009, 115(9):1924-1931. doi:10.1002/cncr.24207
Article
Google Scholar
Seidman AD: Gemcitabine as single-agent therapy in the management of advanced breast cancer. Oncology (Williston Park) 2001, 15(2 Suppl 3):11-14.
Google Scholar
Spielmann M, Llombart-Cussac A, Kalla S, Espie M, Namer M, Ferrero JM, Dieras V, Fumoleau P, Cuvier C, Perrocheau G, Ponzio A, Kayitalire L, Pouillart P: Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 2001, 60(4):303-307. doi:58524
Article
Google Scholar
Tripathy D: Overview: gemcitabine as single-agent therapy for advanced breast cancer. Clin Breast Cancer 2002, 3(Suppl 1):8-11.
Article
Google Scholar
von Minckwitz G, Martin M, Wilson G, Alba E, Schmidt M, Biganzoli L, Awada A: Optimizing taxane use in MBC in the emerging era of targeted chemotherapy. Crit Rev Oncol Hematol 2013, 85(3):315-331. doi:10.1016/j.critrevonc.2012.09.009
Article
Google Scholar
Yardley DA: Integrating gemcitabine into breast cancer therapy. Oncology (Williston Park) 2004, 18(14 Suppl 12):37-48.
Google Scholar
Zielinski C, Beslija S, Mrsic-Krmpotic Z, Welnicka-Jaskiewicz M, Wiltschke C, Kahan Z, Grgic M, Tzekova V, Inbar M, Cervek J, Chernozemsky I, Szanto J, Spanik S, Wagnerova M, Ghilezan N, Pawlega J, Vrbanec D, Khamtsov D, Soldatenkova V, Brodowicz T: Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial. J Clin Oncol 2005, 23(7):1401-1408. doi:10.1200/jco.2005.12.106
Article
Google Scholar